Despite Limited Treatments, Advances in Frontline HCC and High-Risk RCC HeraldedFebruary 6th 2021
Delivering the right treatment to the right patient with an eye toward tumor characteristics and gene alterations is at the heart of precision medicine. In this issue, we explore ongoing efforts to achieve precision medicine across disease settings.
NCI-MATCH Trial Explores Tumor-Agnostic ApproachFebruary 3rd 2021
A tumor-agnostic approach in which treatment is developed based on a tumor’s genetic and molecular features without regard to the cancer type or primary tumor location in the body, is the focus of the National Cancer Institute -MATCH trial.
Immunotherapy Combo Use Supported in MesotheliomaFebruary 1st 2021
Patient-reported outcomes outcomes from the Check-Mate 743 trial demonstrated improved symptom burden and maintained overall health status with the use of nivolumab/ipilimumab over chemotherapy, in patients with unresectable malignant pleural mesothelioma.